Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

Completers Contrave Placebo p-value** Contrave Placebo p-value** Weight Loss (%) 9.3% 5.1% <0.001 11.5% 7.3% <0.001 Weight Loss (lbs) 20.3 lbs 11.0 lbs <0.001 25.0 lbs 16.0 lbs <0.001 greater than or equal to 5% weight loss 66.4% 42.5% <0.001 80.4% 60.4% <0.001 greater than or equal to 10% weight loss 41.5% 20.2% <0.001 55.2% 30.2% <0.001 greater than or equal to 15% weight loss 29.1% 10.9% <0.001 39.5% 17.9% <0.001 * ITT, last observation carried forward (LOCF) analysis included all randomized subjects with baseline and at least one post-baseline measurement while on study drug. ** p-value based on difference between Contrave and placebo.

In order to assess how early study drug discontinuations affect efficacy measures, a post-hoc sensitivity analysis was conducted. In this analysis, we included all randomized patients who received at least one dose of study drug and had at least one post-baseline measurement of body weight. Contrave patients lost an average of 17.6 pounds, or 8.1% of their baseline body weight, versus 10.6 pounds, or 4.9% of baseline body weight for placebo patients. This analysis also showed that 56.8% of Contrave patients lost at least 5% of their body weight compared to 42.9% for placebo patients. All of these results remained highly statistically significant.

Secondary endpoints that demonstrated clinically and statistically significant improvements over placebo included HDL, triglycerides, waist circumference and hsCRP, markers of cardiovascular risk. Contrave patients also demonstrated improvements in quality of life compared to placebo patients as measured by the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) scale, and decreases in sel
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage ... upcoming presentations at three investor conferences: , Wednesday, ... Conference in New York at the ... 2:00 PM at the BioCentury NewsMakers Conference in ... Conference Center , Thursday, September 17 at 9:30 AM ...
(Date:9/2/2015)... Florida (PRWEB) , ... September 02, 2015 , ... ... been treated and managed with the use of special anti-vascular endothelial growth factor ... in many more patients, currently does not have a scientific protocol for the ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... development of botanical and plant-derived compounds. BCC Research reveals in its new ... 2020 because this market defines the category and generates the most market demand. ...
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Life Sciences Industry in ... Western ... (PLSG), the organization providing capital investments and,customized company formation and ... the PLSG has reached a,significant milestone with over $10 million ...
... Huifeng,Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), ... and pharmaceutical raw materials,for use in pharmaceutical, ... will release financial results for their first ... 2008, after the US markets close.,Huifeng,s earnings ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... from Merz Pharmaceuticals GmbH (Merz) for sales,by ... for the treatment of,moderate-to-severe Alzheimer,s disease during ... exclusive marketing agreement, NTI currently receives,quarterly royalty ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Tops $10M in Company Investments 2The Pittsburgh Life Sciences Greenhouse Tops $10M in Company Investments 3
(Date:8/24/2015)... Calif. , Aug. 24, 2015  Based on its ... recognizes DERMALOG with the 2015 African Biometrics Company of the ... has achieved substantial commercial success in Africa ... , where it has implemented one of the largest ... banks as well as the Central Bank of ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)... , Aug. 12, 2015  New research ... can attack Android phones to steal users, fingerprints. ... increasing availability of fingerprint scanners on mobile devices, ... concern. To secure biometrics on mobile devices, HYPR ... augment these convenient authentication systems with strong cryptographic ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... of the Blackleg fungus, which causes the most damaging disease ... time by a team of French and Australian scientists. ... University of Melbourne, who led the Australian research team, said ... Blackleg disease. "The 12,500 genes that constitute the genetic ...
... Optiqua Technologies Pte Ltd is collaborating with Nanyang ... in biomolecular sciences and sensor technology. Optiqua, ... provides the international water industry with innovative products ... detection of contaminants in water. The sensor technology ...
... , Scientists today agree that there are five molecules that ... an estimated five million Americans. The potency of these molecules ... Prof. Daniel Michaelson of Tel Aviv University,s Department ... Sciences has illuminating news about one of these five molecules ...
Cached Biology News:Uncovering the genome secrets of the Blackleg fungus 2Optiqua-NTU partnership to develop next-generation sensor technology 2Good diets fight bad Alzheimer's genes 2
... FastPlax Titer Kit is designed for determination of ... 46 days as in other methods. Classical determination ... of plaques, but the FastPlax Kit takes advantage ... gp64 glycoprotein on the cell surface as early ...
... software for all your biopharmaceutical applications needs. ... single, scalable software package. The graphical user ... control of all Freedom instruments from simple ... with one liquid handling arm up to ...
... an advanced system for isolating DNA from agarose gels ... directly for any downstream application. Features ... in 56 minutes Low melting point agarose not ... gels No specialised equipment required DNA is ...
... incubators with rotators. Graduated, 35 mm ... plug-seal screw-cap with O-ring for a ... to accept different size hybridization membranes. ... separately. • Comp Dim: tube L ...
Biology Products: